 Molecular Templates Inc NASDAQ: MTEM has decided to discontinue the development of MT-3724, its only first-generation engineered toxin bodies ETB, and focus its resources on the development of next-generation ETBs. In November last year, FDA instituted a partial clinical hold on Phase 2 MT-3724 monotherapy study following a treatment-related fatality in one subject who experienced Grade 5 capillary leak syndrome. 